Trends of liposomal bupivacaine utilization in major lower extremity total joint arthroplasty in the USA: a population-based study
Authors' conclusion
Liposomal bupivacaine use peaked around 2015 and has been declining thereafter on individual patient and hospital levels.
Study context
- Population
- Adults undergoing elective total joint arthroplasty, Premier Healthcare Database, 2012–2021
- Participants
- 103,165 total joint arthroplasty cases
- Outcome
- Prevalence and trends of liposomal bupivacaine utilization (patient and hospital levels)
Methodological detailspopulation-based, database study
- Population-based
- Database study
Main finding
As reported in the abstract
Liposomal bupivacaine use (patient level)
Use in 2012
0.4%
Use in 2015 (peak)
22.8%
Annual decrease after 2015
≈1%-3%
Use in 2021
15.7%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Retention of liposomal bupivacaine by hospital characteristics (time to termination)Non-teaching vs Teaching · non-teaching retained longer · log-rank tests | P = 0.023 |
| Retention of liposomal bupivacaine by hospital characteristics (time to termination)South and West vs Midwest/Northeast · South and West retained longer · log-rank tests | P = 0.014 |
Hospital-level use
- Hospitals ever using liposomal bupivacaine
- ≈60%
- Initiation in 2013
- 32.8%
- Initiation in 2021
- 4.3%
- Termination in 2014
- 1.4%
- Termination in 2019
- 9.9%
- Initiation peaked in 2014
Original publication
Trends of liposomal bupivacaine utilization in major lower extremity total joint arthroplasty in the USA: a population-based study. Reg Anesth Pain Med. Published 11 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →